Acerus Pharmaceuticals (TRLPF) Stock Price, News & Analysis

Company Overview

Acerus Pharmaceuticals Corporation is a specialty pharmaceutical company focused on developing and commercializing hormone-based therapies for men’s and women’s health. The company’s research and development programs target areas such as testosterone replacement, women’s health, and urology, with an emphasis on long-acting formulations and novel delivery systems.

The company’s lead marketed product is AVEED, a long-acting injectable testosterone undecanoate formulation approved by the U.S. Food and Drug Administration and Health Canada for testosterone replacement therapy in adult men with primary hypogonadism or hypogonadotropic hypogonadism. In addition, Acerus offers Tefina, a subcutaneous norethindrone implant for endometriosis, and maintains a pipeline of early-stage candidates aimed at women’s reproductive health and other hormonal disorders.

Acerus Pharmaceuticals operates primarily in North America, with commercial activities in the United States and Canada. The company also pursues strategic licensing and distribution partnerships to extend its products into European and other international markets. Manufacturing and quality control functions are managed through contract development and manufacturing organizations (CDMOs) that meet regulatory standards in multiple jurisdictions.

Founded under a different corporate name and rebranded as Acerus in 2010, the company is led by President and Chief Executive Officer Greg Heil, whose leadership team brings experience in pharmaceutical R&D, regulatory affairs and commercialization. Acerus continues to invest in its pipeline and partnerships to address unmet needs in hormone therapy and specialty care.

Key Stats

• Today's Range: $0.22 to $0.22
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.08 to $0.34
• Volume: N/A
• Average Volume: 5,474 shs
• Market Capitalization: $56.90 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRLPF Stock Analysis - Frequently Asked Questions

How have TRLPF shares performed this year?

Acerus Pharmaceuticals' stock was trading at $0.22 on January 1st, 2025. Since then, TRLPF shares have increased by 0.0% and is now trading at $0.22.

How were Acerus Pharmaceuticals' earnings last quarter?

Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) posted its quarterly earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The specialty pharmaceutical company had revenue of $1.58 million for the quarter. Acerus Pharmaceuticals had a negative net margin of 254.66% and a negative trailing twelve-month return on equity of 346.72%.

How do I buy shares of Acerus Pharmaceuticals?

Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/05/2018
• Today: 9/16/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRLPF
• CIK: N/A
• Web: www.aceruspharma.com
• Phone: 416-679-0771
• Fax: N/A
• Employees: 29
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): ($0.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.79 million
• Net Margins: -254.66%
• Pretax Margin: N/A
• Return on Equity: -346.72%
• Return on Assets: -94.54%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 1.35
• Quick Ratio: 0.90

Sales & Book Value

• Annual Sales: $7.38 million
• Price / Sales: 7.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 258,615,000
• Free Float: N/A
• Market Cap: $56.90 million
• Optionable: Not Optionable
• Beta: 2.60